2552.HK - Hua Medicine (Shanghai) Ltd.

HKSE - HKSE Delayed Price. Currency in HKD
6.900
+0.010 (+0.15%)
As of 3:34PM HKT. Market open.
Stock chart is not supported by your current browser
Previous Close6.900
Open7.000
Bid6.910 x 0
Ask7.180 x 0
Day's Range6.900 - 7.000
52 Week Range6.000 - 8.990
Volume16,500
Avg. Volume266,922
Market Cap6.475B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire2 months ago

    Hua Medicine – Business & Pipeline Update

    TrialProductsExploratoryNDA EnablingDescription / Indication HMM0301Dorzagliatin (HMS5552) Phase III ongoingDrug-naïve T2D HMM0302Dorzagliatin + Metformin Phase III.

  • GlobeNewswire3 months ago

    Hua Medicine Initiates First Combination Study of Dorzagliatin with SGLT-2 in the United States

    Hua Medicine (2552.HK), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, announced today dosing of the first patient in a Phase I drug-drug interaction trial of HMS5552 (dorzagliatin) in patients with insufficiently controlled T2D with metformin, DPP-4 inhibitor, or SGLT2 inhibitor, alone or in combination therapy (metformin plus DPP-4 inhibitor, or metformin plus SGLT-2 inhibitor). The trial is a pharmacokinetic and pharmacodynamic study of dorzagliatin in combination with empagliflozin to investigate the PK/PD of each drug alone or in combination. The primary endpoints are pharmacokinetic interaction between dorzagliatin and empagliflozin, and safety and tolerability of dorzagliatin with simultaneous administration of empagliflozin.

  • GlobeNewswire5 months ago

    Hua Medicine completes patient enrollment for Phase III monotherapy trial of dorzagliatin

    Hua Medicine (2552.HK), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, announced today the completion of patient enrollment for a Phase III monotherapy trial of HMS5552 (dorzagliatin).  Hua Medicine therefore expects to release the topline results in 4th quarter of 2019. “I am very proud to announce this milestone,” said Dr. Li Chen, Chief Executive Officer of Hua Medicine. “With 120 million Type 2 diabetics in China, this gets us one step closer to bringing dorzagliatin, a novel, first-in-class drug to the Chinese market.

  • GlobeNewswire6 months ago

    Hua Medicine Initiates First Combination Study of Dorzagliatin with a DPP-4 Inhibitor in the United States

    Stock Code: 2552.HK) a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes (T2D), announced today dosing of the first patient in a clinical trial of HMS5552 (dorzagliatin) in patients with insufficiently controlled blood glucose levels with metformin, DPP-4 inhibitor, or SGLT-2 inhibitor, alone or in combination therapy. The trial is a pharmacokinetic (PK) and pharmacodynamic (PD) study of dorzagliatin in combination with sitagliptin to investigate the PK/PD of each drug alone or in combination. The primary endpoints are pharmacokinetic and pharmacodynamic interaction between dorzagliatin and sitagliptin, and safety and tolerability of dorzagliatin with simultaneous administration of sitagliptin.

  • Reuters7 months ago

    China's Junshi Biosciences raises $394 mln after pricing IPO at bottom of range -sources

    Chinese biotech startup Shanghai Junshi Biosciences Co Ltd has raised $394 million after pricing its Hong Kong initial public offering (IPO) at the bottom of a marketed range, two people familiar with the share sale said on Monday. The firm aims to take advantage of rules introduced by Hong Kong's stock exchange in April allowing listings from pre-revenue biotechs, as the bourse competes to attract startups. Junshi Biosciences priced shares at HK$19.38 ($2.48) each, the people said, having indicated a price of up to HK$20.38.

  • Investing.com9 months ago

    China’s Innovent Extends Gain from Solid HK IPO

    Investing.com - The shares of China’s Innovent Biologics Inc (HK:1801) continued to rise on Friday morning in Asia, two days after their initial public offering.

  • Reuters9 months ago

    China's Innovent Biologics looks to raise up to $422 mln in HK IPO - sources

    Chinese biotech firm Innovent Biologics is looking to raise up to $422 million in its Hong Kong IPO, three sources said, in what could be the biggest biotech IPO in the financial hub this year. Innovent, which is backed by mutual fund giant Fidelity and Singapore state investor Temasek, has set an indicative price range of HK$12.5-HK$14.00 ($1.59-$1.79) per share for its initial public offering (IPO), the sources said, giving the company a valuation of about $2 billion. It is the latest company looking to take advantage of new rules introduced by the Hong Kong stock exchange to woo early-stage drug developers, after Ascletis Pharma, Hua Medicine and Nasdaq-listed BeiGene.